UNIVERSITY OF CALIFORNIA, IRVINE

Metabolomics shows potential to improve breast cancer detection, offering greater reliability and less discomfort. Studies reveal metabolic signatures accurately identify cancer markers, with promising AUC values. Current screening methods like mammograms risk eroding public trust due to false positives, highlighting the need for better alternatives.

Precision medicine in cancer care faces barriers like unequal access to biopsies and biomarker testing. Collaboration, standardized protocols, and education are key to overcoming these challenges, ensuring equitable access to targeted therapies.

AutoChamber AI, with FDA breakthrough device designation, enhances CT scans to evaluate cardiovascular risks, including heart failure, atrial fibrillation, and stroke, potentially improving outcomes through earlier intervention.

HeartLung Technologies' AI-enabled AutoChamber received FDA's 'Breakthrough Medical Device' designation for early detection of heart disease and lung cancer. AutoChamber analyzes cardiac chambers and left ventricular wall mass in non-contrast CT scans, potentially identifying high-risk patients for cardiovascular disease and sudden cardiac death.

HeartLung Technologies introduces AutoChamber™ AI, an FDA-designated Breakthrough AI for detecting asymptomatic heart disease in CT scans, enabling evaluation of coronary disease, heart failure, atrial fibrillation, and stroke risk. AutoChamber™ leverages deep learning and chest CT scans to flag high-risk patients, potentially saving lives by facilitating earlier intervention.

The Biotechnology Instruments Market is projected to grow from USD 85.4 billion in 2023 to USD 127.4 billion by 2033, at a CAGR of 4.12%. These instruments are vital for biotechnology, healthcare, and pharmaceutical industries, enhancing research in genomics, genetic engineering, and personalized medicine. The market saw significant growth during the COVID-19 pandemic, driven by increased R&D and demand for PCR kits. Emerging trends include digitization of clinical trials, AI integration, and development of bioplastics and biofuels.

3D printed customized eyeglasses improved vision in children with amblyopia or strabismus in Ensenada, Mexico, significantly reducing refractive errors and earning high satisfaction ratings from children and parents.

Researchers identified new drug targets for retinitis pigmentosa and other inherited retinal diseases, revealing shared critical pathways in disease models, published in Molecular & Cellular Proteomics.

Booster Therapeutics, backed by $15 million, aims to expand protein degradation therapies by focusing on the 20S proteasome, which can degrade multiple proteins without a molecular tag, initially targeting neurodegeneration. The startup's DGRADX platform uses computational techniques to identify and optimize small molecule proteasome activators, with potential applications in Parkinson’s and Alzheimer’s diseases.

Neuvivo has filed an FDA application for NP001 (sodium chlorite) to treat ALS, based on Phase 2 trials showing it slowed disease progression and preserved lung function in patients with high inflammation. If approved, NP001 could be the first disease-modifying therapy for ALS, targeting immune cells to reduce inflammation and restore immune balance.